Jason J. Luke, MD, FACP
The addition of pembrolizumab (Keytruda) to stereotactic body radiotherapy (SBRT) induced an objective response rate of 13.2% among patients with advanced solid tumors, according to a phase I study published in the Journal of Clinical Oncology
Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors [published online February 13, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.76.2229.
... to read the full story